Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 41Prostatic Neoplasms 32Ovarian Neoplasms 23Testicular Neoplasms 18Carcinoma, Transitional Cell 16Carcinoma, Renal Cell 16Carcinoma, Non-Small-Cell Lung 15Neoplasms 13Melanoma 13Testicular Germ Cell Tumor 12Colorectal Neoplasms 12Breast Neoplasms 12Neoplasm Metastasis 10Urethral Neoplasms 9Stomach Neoplasms 9Lung Neoplasms 9Endodermal Sinus Tumor 9Teratoma 8Pancreatic Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Embryonal 8Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Seminoma 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Esophageal Neoplasms 5Endometrial Neoplasms 5Penile Neoplasms 4

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Paclitaxel × Genitourinary × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡